留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《2022 NCCN胃癌临床实践指南》更新解读

刘媛 赵林

刘媛, 赵林. 《2022 NCCN胃癌临床实践指南》更新解读[J]. 协和医学杂志, 2022, 13(6): 999-1004. doi: 10.12290/xhyxzz.2022-0271
引用本文: 刘媛, 赵林. 《2022 NCCN胃癌临床实践指南》更新解读[J]. 协和医学杂志, 2022, 13(6): 999-1004. doi: 10.12290/xhyxzz.2022-0271
LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. doi: 10.12290/xhyxzz.2022-0271
Citation: LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. doi: 10.12290/xhyxzz.2022-0271

《2022 NCCN胃癌临床实践指南》更新解读

doi: 10.12290/xhyxzz.2022-0271
详细信息
    通讯作者:

    赵林, E-mail: wz20010727@aliyun.com

  • 中图分类号: R735.2;R730.5

Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer

More Information
  • 摘要: 近日, 美国国立综合癌症网络发布了2022年最新版胃癌临床实践指南。该版指南不仅细化了对腹腔转移性肿瘤的评估、术后放疗的适应证以及三药联合化疗的推荐, 更为重要的是首次推荐高通量测序技术用于微卫星不稳定(microsatellite instability, MSI)/错配修复(mismatch repair, MMR)状态的检测, 并推荐将MSI/MMR状态检测扩大至全人群。同时, 在后线治疗中新增了数种基于分子分型的新药推荐, 指明了未来胃癌精准治疗的方向。本文将对新版胃癌临床实践指南, 特别是其更新部分进行解读, 以期为临床实践提供指导和帮助。
    作者贡献:刘媛负责查阅文献资料、撰写论文;赵林负责指导、修改、审核论文。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20: 167-192. doi:  10.6004/jnccn.2022.0008
    [2] International Agency for Research on Cancer. GLOBOCAN 2020: stomach cancer fact sheet[EB/OL]. (2020-12)[2022-05-01]. https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf.
    [3] Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study[J]. EClinicalMedicine, 2022, 47: 101404. doi:  10.1016/j.eclinm.2022.101404
    [4] Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment[J]. Cancer Manag Res, 2018, 10: 239-248. doi:  10.2147/CMAR.S149619
    [5] Ma J, Shen H, Kapesa L, et al. Lauren classification and individualized chemotherapy in gastric cancer[J]. Oncol Lett, 2016, 11: 2959-2964. doi:  10.3892/ol.2016.4337
    [6] Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology[J]. J Gastrointest Oncol, 2012, 3: 251-261.
    [7] Crew KD, Neugut AI. Epidemiology of gastric cancer[J]. World J Gastroenterol, 2006, 12: 354-362. doi:  10.3748/wjg.v12.i3.354
    [8] Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2017.
    [9] Sarela AI, Lefkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging[J]. Am J Surg, 2006, 191: 134-138. doi:  10.1016/j.amjsurg.2005.10.015
    [10] Abdalla EK, Pisters PWT. Staging and preoperative evaluation of upper gastrointestinal malignancies[J]. Semin Oncol, 2004, 31: 513-529. doi:  10.1053/j.seminoncol.2004.04.014
    [11] Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients[J]. Ann Surg Oncol, 2010, 17: 3173-3180. doi:  10.1245/s10434-010-1183-0
    [12] Song L, Qian X, Xin D, et al. Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer: A meta-analysis and systematic review[EB/OL]. [2022-05-01]. https://meetings.asco.org/abstracts-presentations/204818.
    [13] Andre T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase Ⅱ study[EB/OL]. [2022-05-01]. https://meetings.asco.org/abstracts-presentations/205214.
    [14] Trabucco SE, Gowen K, Maund SL, et al. A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67, 000 Patient Samples[J]. J Mol Diagn, 2019, 21: 1053-1066. doi:  10.1016/j.jmoldx.2019.06.011
    [15] Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel[J]. Clin Cancer Res, 2019, 25: 7035-7045. doi:  10.1158/1078-0432.CCR-19-1324
    [16] Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma[J]. Clin Cancer Res, 2018, 24: 6248-6256. doi:  10.1158/1078-0432.CCR-18-1128
    [17] Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastic cancer[J]. J Clin Oncol, 2010, 28: 2430-2436. doi:  10.1200/JCO.2009.26.9654
    [18] Park SH, Sohn TS, Lee J, et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrence chemoradiotherapy in gastric cancer: final report of the Adjuvant Chemoradiotherapy In Stomach Tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33: 3130-3136. doi:  10.1200/JCO.2014.58.3930
    [19] Lee J, Lim do H, Kim S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol, 2012, 30: 268-273.
    [20] Park SH, Lim DH, Sohn TS, et al. A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiotion with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial[J]. Ann Oncol, 2021, 32: 368-374. doi:  10.1016/j.annonc.2020.11.017
    [21] Al-Batran SE, Pauligk C, Homann N, et al. The feasi-bility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)[J]. Eur J Cancer, 2013, 49: 835-842. doi:  10.1016/j.ejca.2012.09.025
    [22] Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oncol, 2006, 24: 4991-4997. doi:  10.1200/JCO.2006.06.8429
    [23] Elsaid AA, Elkerm Y. Final results of a randomized phase Ⅲ trial of docetaxel, carboplatin and 5FU versus epiru-bicin, cisplatin and 5FU for locally advanced gastric cancer[J]. J Clin Oncol, 2005, 23: 4014. doi:  10.1200/jco.2005.23.16_suppl.4014
    [24] Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase Ⅱstudy[J]. Ann Oncol, 2015, 26: 149-156. doi:  10.1093/annonc/mdu496
    [25] Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase Ⅱ study of modified docetaxel, cisplatin, and fluorouracil(DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium[J]. J Clin Oncol, 2015, 33: 3874-3879. doi:  10.1200/JCO.2015.60.7465
    [26] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemother-apy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376: 687-697. doi:  10.1016/S0140-6736(10)61121-X
    [27] Chung HC, Bang YJ, Fuchs CS, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811[J]. Future Oncol, 2021, 17: 491-501. doi:  10.2217/fon-2020-0737
    [28] Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398: 27-40. doi:  10.1016/S0140-6736(21)00797-2
    [29] Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383: 31-39. doi:  10.1016/S0140-6736(13)61719-5
    [30] Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15: 1224-1235. doi:  10.1016/S1470-2045(14)70420-6
    [31] Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial[J]. JAMA Oncol, 2020, 6: 1766-1772. doi:  10.1001/jamaoncol.2020.4515
    [32] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38: 1-10.
  • 加载中
计量
  • 文章访问数:  1168
  • HTML全文浏览量:  103
  • PDF下载量:  297
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-11
  • 录用日期:  2022-05-23
  • 网络出版日期:  2022-06-22
  • 刊出日期:  2022-11-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!